Hyderabad Telangana, India

Ramalingam Thallapalli

This inventor holds 1 USPTO granted patent. Top assignee: Council of Scientific and Industrial Research. Active years: 2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ramalingam Thallapalli. Retrieved from https://idiyas.com/inventor/ramalingam-thallapalli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ramalingam Thallapalli: Innovator in Hypoglycemic Agents

Introduction

Ramalingam Thallapalli is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of hypoglycemic agents. His work is aimed at addressing critical health issues such as diabetes.

Latest Patents

Thallapalli holds a patent for his invention titled "1-(aryloxy)propionoyl-2-arylsulfonyl hydrazines, process for preparation thereof and use thereof as hypoglycemic agents." This invention relates to the synthesis of 1-(aryloxy)propionoyl-2-arylsulfonyl hydrazines, which are useful as hypoglycemic agents. The process he developed is significant for the treatment of diabetes, showcasing his commitment to improving health outcomes.

Career Highlights

Ramalingam Thallapalli is associated with the Council of Scientific and Industrial Research, where he continues to engage in innovative research. His work has led to advancements in the pharmaceutical industry, particularly in the area of diabetes management.

Collaborations

Thallapalli has collaborated with notable colleagues, including Venkata Durga Nageswar Yadavalli and Ramakrishna Sistla. These collaborations have further enhanced the impact of his research and innovations.

Conclusion

Ramalingam Thallapalli is a distinguished inventor whose work in hypoglycemic agents is making a difference in diabetes treatment. His contributions reflect a dedication to scientific advancement and public health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…